Kaiser Permanente is leading the way with vaccines going to trial, one of the first three going into human testing:
Leading the way is Kaiser Permanente Washington Research Institute in Seattle, which began testing 45 healthy adult volunteers earlier this month. The other two front-runners are the Beijing Institute of Biotech and CanSino Biologics, and the University of Oxford in the United Kingdom.
?We?re going to need multiple vaccines to be able to fully stop the pandemic.?
One reason is that patients will react to the vaccine differently, Fuller said. For example, a vaccine that works well in young adults may not be as effective among older populations or for people with underlying health conditions.
So it is all hands on deck, and the good news is that Kaiser is pursuing a faster way to get vaccines through trials and testing and into general availability.